Literature DB >> 12754175

CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.

Raymond C Givens1, Yvonne S Lin, Amy L S Dowling, Kenneth E Thummel, Jatinder K Lamba, Erin G Schuetz, Paul W Stewart, Paul B Watkins.   

Abstract

A single-nucleotide polymorphism (A6986G) in the cytochrome p-450 3A5 (CYP3A5) gene distinguishes an expressor (*1) and a reduced-expressor (*3) allele and largely predicts CYP3A5 content in liver and intestine. CYP3A5 is the prevailing CYP3A isoform in kidney. We report that, among renal microsomes from 21 organ donors, those from *1/*3 individuals had at least eightfold higher mean kidney microsomal CYP3A5 content and 18-fold higher mean CYP3A catalytic activity than did those from *3/*3 individuals (P = 0.0001 and P = 0.0137, respectively). We also report significant associations between the A6986G polymorphism and systolic blood pressure (P = 0.0007), mean arterial pressure (P = 0.0075), and creatinine clearance (P = 0.0035) among 25 healthy African-American adults. These associations remained significant when sex, age, and body mass index were taken into account. The mean systolic blood pressure of homozygous CYP3A5 expressors (*1/*1) exceeded that of homozygous nonexpressors (*3/*3) by 19.3 mmHg. We speculate whether a high CYP3A5 expressor allele frequency among African-Americans may contribute to a high prevalence of sodium-sensitive hypertension in this population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754175     DOI: 10.1152/japplphysiol.00322.2003

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  33 in total

1.  PharmGKB summary: very important pharmacogene information for CYP3A5.

Authors:  Jatinder Lamba; Joan M Hebert; Erin G Schuetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

Review 2.  Proximal tubular function and salt sensitivity.

Authors:  Michel Burnier; Murielle Bochud; Marc Maillard
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

Review 3.  The pharmacogenetics research network: from SNP discovery to clinical drug response.

Authors:  K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

Review 4.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies.

Authors:  Yi-Ping Zong; Zi-Jie Wang; Wan-Li Zhou; Wei-Min Zhou; Tie-Liang Ma; Zheng-Kai Huang; Chun-Chun Zhao; Zhen Xu; Ruo-Yun Tan; Min Gu
Journal:  World J Pediatr       Date:  2017-05-24       Impact factor: 2.764

6.  Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.

Authors:  Hye-In Lee; Ji-Young Byeon; Young-Hoon Kim; Choong-Min Lee; Chang-Ik Choi; Choon-Gon Jang; Jung-Woo Bae; Yun Jeong Lee; Seok-Yong Lee
Journal:  Eur J Clin Pharmacol       Date:  2018-07-24       Impact factor: 2.953

7.  Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

Authors:  M A Perera; R K Thirumaran; N J Cox; S Hanauer; S Das; C Brimer-Cline; V Lamba; E G Schuetz; M J Ratain; A Di Rienzo
Journal:  Pharmacogenomics J       Date:  2008-09-30       Impact factor: 3.550

8.  Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.

Authors:  S Zheng; Y Tasnif; M F Hebert; C L Davis; Y Shitara; J C Calamia; Y S Lin; D D Shen; K E Thummel
Journal:  Clin Pharmacol Ther       Date:  2012-10-17       Impact factor: 6.875

9.  Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.

Authors:  Chin B Eap; Thierry Buclin; Elisabeth Hustert; Gabriela Bleiber; Kerry Powell Golay; Anne-Catherine Aubert; Pierre Baumann; Amalio Telenti; Reinhold Kerb
Journal:  Eur J Clin Pharmacol       Date:  2004-04-28       Impact factor: 2.953

10.  Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine.

Authors:  Xiaoping Chen; Haijian Wang; Gangqiao Zhou; Xiumei Zhang; Xiaojia Dong; Lianteng Zhi; Li Jin; Fuchu He
Journal:  Environ Health Perspect       Date:  2009-06-18       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.